Tag: cannabis
-
![Canntab Therapeutics (PILL.C): The Canadian weed sector is struggling, but new consumer products have room to scale]()
Canntab Therapeutics (PILL.C): The Canadian weed sector is struggling, but new consumer products have room to scale
If we’re honest about it – if we’re REALLY honest about it – Canada has fumbled its advantage in the cannabis sector. First to market, first to raise hundreds of millions in financing, first to legalize, first to recreationalize (not a word but I’m on a roll), and it’s all really been for naught. In…
-
![Harborside (HBOR.C) raises $20 million, narrows focus on California, projects 2021 cannabis revenues equal to its current market cap]()
Harborside (HBOR.C) raises $20 million, narrows focus on California, projects 2021 cannabis revenues equal to its current market cap
The January 20, 2021 press release declared that HBOR is “expecting gross revenues in line with previously issued guidance of approximately $61 – 63 million, and positive EBITDA”.
-
![Xphyto Therapeutics (XPHY.C) lays out their milestones and strategic guard-rails for 2021]()
Xphyto Therapeutics (XPHY.C) lays out their milestones and strategic guard-rails for 2021
In lieu of the American markets not opening today courtesy of the civic holiday, Xphyto Therapeutics (XPHY.C) has elected to provide a glimpse into their business strategy and milestones for 2021. As an overview, the company sees itself on the edge of a transformational change as their product development programs go from the laboratory to…
-
![Heritage Cannabis (CANN.C) launches new consumer product as global cannabis stocks rally 61% in Q4, 2020]()
Heritage Cannabis (CANN.C) launches new consumer product as global cannabis stocks rally 61% in Q4, 2020
CANN focuses on extraction and the creation of derivative products for recreational and medical consumers.
-
![Harborside (HBOR.C) buys another California dispensary]()
Harborside (HBOR.C) buys another California dispensary
With HBOR’s track record of revenue-growth-per-location, the addition of FGW is likely to accelerate revenue growth.
-
![Pure Extracts (PULL.C) begins mushroom build-out]()
Pure Extracts (PULL.C) begins mushroom build-out
Pure Extracts is targeting the commercial cannabis and psychedelics sector, backed by deep extraction and production expertise.
-
Heritage Cannabis (CANN.C) up hard on Alberta sales news
No cannabis companies splits investors squarely down the middle like Heritage Cannabis (CANN.C). Despite ongoing good news and deals with larger players, a sizable section of the legacy cannabis investing community has just never been able to get on board with the Canadian weedco – until this week. Our Joseph Morton blew the trumpet on…
-
Revive Therapeutics (RVV.C) shareholders experience intense vertigo
Investor focus is currently bifurcated between a potential FDA bucillamine approval, and RVV’s ambitions and partnerships in the shroom space.
-
![Biotech Blitz: Xphyto (XPHY.C), Theralase (TLT.V), Caladrius (CLBS.Q), Volition Rx (VNRX.NYSE), Kane Biotech (KNE.V) and Bionexus (BGLC.OTC) stand & deliver]()
Biotech Blitz: Xphyto (XPHY.C), Theralase (TLT.V), Caladrius (CLBS.Q), Volition Rx (VNRX.NYSE), Kane Biotech (KNE.V) and Bionexus (BGLC.OTC) stand & deliver
On Thursday, December 17th, 2020 the Virtual Life Sciences Investor Forum (VLSIF) presents a six biotech companies.
-
![Core One Labs (COOL.C) unhalted today, and it will be a horror show: But that’s okay]()
Core One Labs (COOL.C) unhalted today, and it will be a horror show: But that’s okay
Halted since July of this year, right in the midst of a six week rise, the pubco formerly known as Lifestyle Delivery Systems, now Core One Labs (COOL.C), unhalted today and, as expected, took an immediate stock price dive. Having shut the door to trading in July at $0.73 as the exchange enforced a change…
